Skip to main content

Market Overview

Jefferies Sees Limited Impact To Gilead From Regulus' HCV Candidate's Clinical Hold

Jefferies Sees Limited Impact To Gilead From Regulus' HCV Candidate's Clinical Hold

Shares of Regulus Therapeutics Inc (NASDAQ: RGLS) were down almost 48 percent on Tuesday, after the company said Monday the FDA had placed its lead product candidate, RG-101 – for the treatment of hepatitis C virus infection, on clinical hold.

Following the news, Jefferies analysts reiterated a Hold and $96 price target on shares of Gilead Sciences, Inc. (NASDAQ: GILD), which gained about 5 percent on Tuesday. In a note issued late-Monday, the experts believe the impact the event will have on Gilead will be “limited.”

Although RG101 had revealed potential to shorten the duration of treatment for competitor oral regimens, Jefferies analysts view “HCV price compression and pt. flows as more important NT/MT risks/uncertainties for GILD.”

Having said this, the experts added they would need more details before being able to determine if RG-101 can still move forward. However, they do think “the safety track record and oral administration of Harvoni and other marketed GILD HCV products set a high bar.”

Disclosure: Javier Hasse holds no interest in any of the securities or entities mentioned above.

Latest Ratings for GILD

Apr 2021Morgan StanleyMaintainsOverweight
Apr 2021BernsteinUpgradesMarket PerformOutperform
Mar 2021RedburnUpgradesNeutralBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings


Related Articles (GILD + RGLS)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Health Care Price Target Reiteration FDA Best of Benzinga

Latest Ratings

ICADGuggenheimInitiates Coverage On24.0
SMBKRaymond JamesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at